Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:MXCTNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$37.61+1.7%$37.24$30.04▼$67.88$3.25B1.881.68 million shs975,656 shsMXCTMaxCyte$2.24+1.6%$2.65$2.10▼$5.26$236.56M1.38579,670 shs958,590 shsVRTXVertex Pharmaceuticals$432.95-0.5%$479.38$377.85▼$519.88$111.04B0.511.41 million shs979,474 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-5.76%+3.90%-2.19%-26.69%-32.45%MXCTMaxCyte+0.92%0.00%-14.40%-44.51%-52.38%VRTXVertex Pharmaceuticals-2.65%+3.36%-8.84%-9.37%-1.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.033 of 5 stars4.31.00.00.02.63.30.6MXCTMaxCyte2.4932 of 5 stars3.52.00.00.01.32.51.3VRTXVertex Pharmaceuticals4.6182 of 5 stars3.35.00.03.34.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7590.80% UpsideMXCTMaxCyte 3.00Buy$7.50235.57% UpsideVRTXVertex Pharmaceuticals 2.59Moderate Buy$515.0418.96% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.005/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.005/7/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $81.005/7/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $82.005/7/2025VRTXVertex PharmaceuticalsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/6/2025VRTXVertex PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/6/2025VRTXVertex PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/6/2025VRTXVertex PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M92.79N/AN/A$22.52 per share1.67MXCTMaxCyte$37.68M6.31N/AN/A$2.23 per share1.00VRTXVertex Pharmaceuticals$11.10B10.02N/AN/A$63.90 per share6.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)MXCTMaxCyte-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A24.732.11-4.86%-2.02%-1.49%8/7/2025 (Estimated)Latest MXCT, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07MXCTMaxCyteN/A9.819.22VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MXCTMaxCyte68.81%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%MXCTMaxCyte3.00%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableMXCTMaxCyte80106.32 million102.67 millionOptionableVRTXVertex Pharmaceuticals4,800256.80 million256.28 millionOptionableMXCT, VRTX, and CRSP HeadlinesRecent News About These CompaniesPrincipal Street Partners LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 8:00 AM | marketbeat.comLantern Wealth Advisors LLC Buys 650 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 7:40 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 7:19 AM | marketbeat.comWoodline Partners LP Acquires 16,653 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 22 at 6:17 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Vident Advisory LLCMay 22 at 5:59 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lifted by Tidal Investments LLCMay 22 at 5:17 AM | marketbeat.comVertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?May 21 at 4:44 PM | msn.comWestport Asset Management Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 7:15 AM | marketbeat.comTriglav Skladi D.O.O. Takes $1.39 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 6:55 AM | marketbeat.comTwinbeech Capital LP Purchases New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 21 at 6:54 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Silvercrest Asset Management Group LLCMay 21 at 5:42 AM | marketbeat.comTema Etfs LLC Takes $4.42 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 6:16 AM | marketbeat.comToronto Dominion Bank Has $43.42 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 6:15 AM | marketbeat.comSnowden Capital Advisors LLC Has $1.91 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 20 at 5:58 AM | marketbeat.comInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 52 Shares of StockMay 20 at 5:18 AM | insidertrades.comVRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue MissMay 20 at 3:45 AM | msn.comVertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy RatingMay 19 at 7:24 AM | tipranks.comRoyal Bank of Canada Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 19 at 6:13 AM | marketbeat.comQuantinno Capital Management LP Has $9.70 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 18, 2025 | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Man Group plcMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseBy Chris Markoch | May 16, 2025View CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseMXCT, VRTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$37.60 +0.62 (+1.66%) As of 03:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.MaxCyte NASDAQ:MXCT$2.24 +0.04 (+1.59%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Vertex Pharmaceuticals NASDAQ:VRTX$432.94 -2.38 (-0.55%) As of 03:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
